Lyme disease can, in rare cases, produce neurological symptoms so close to amyotrophic lateral sclerosis (ALS) that even experienced neurologists initially reach the wrong diagnosis. Case reports document patients with widespread muscle weakness, wasting, twitching, and abnormal reflexes, all hallmarks of ALS, who turned out to have neuroborreliosis, the nervous-system form of Lyme disease. The overlap is uncommon enough that most ALS specialists see it only occasionally, but the stakes are enormous: ALS has no cure, while Lyme disease is treatable with antibiotics.
What the Clinical Overlap Actually Looks Like
ALS attacks motor neurons, the nerve cells that control voluntary muscle movement. As those neurons die, patients develop progressive weakness, muscle wasting, involuntary twitching (fasciculations), and a mix of upper and lower motor neuron signs. Lyme disease, when it invades the nervous system, can inflame spinal nerve roots and the spinal cord itself, producing a remarkably similar picture. In one well-documented case, a 64-year-old man developed rapidly progressive weakness over the course of a single month, affecting his ability to swallow (bulbar muscles), his arms, and his legs. Examination showed widespread weakness, muscle atrophy, fasciculations, and brisk reflexes, and initial electrical testing of his nerves pointed toward ALS.1PubMed. Lyme disease-induced polyradiculopathy mimicking amyotrophic lateral sclerosis
What makes neuroborreliosis capable of this impersonation is the way the Lyme bacterium attacks neural tissue. Animal studies show that the organism triggers inflammation of the membranes surrounding the brain and spinal cord, damages blood vessels supplying the nervous system, and in severe cases causes actual destruction of spinal cord tissue and nerve roots. Nerve cells and the support cells around them can undergo programmed cell death, leading to the kind of denervation (loss of nerve supply to muscles) that normally signals a motor neuron disease.2PubMed Central. Inflammation in the pathogenesis of lyme neuroborreliosis The damage can be widespread enough to affect multiple body regions simultaneously, which is exactly the pattern that triggers concern for ALS.
Clues That Point Toward Lyme Instead of ALS
Despite the overlap, several features can help a clinician suspect Lyme rather than ALS, though none of them are slam-dunk differentiators on their own.
- Sensory involvement: ALS is a pure motor disease. Patients lose strength but keep normal sensation. Lyme neuroborreliosis, because it attacks nerve roots and peripheral nerves rather than motor neurons specifically, often causes numbness, tingling, or pain alongside the weakness. If a patient with an ALS-like presentation also reports burning or shooting pain, that should raise a flag.
- Rate and pattern of decline: Chronic neurological Lyme tends to progress slowly or even plateau. A landmark study found that chronic neurologic abnormalities from Lyme had been present anywhere from three months to 14 years, usually with little progression.3PubMed. Chronic neurologic manifestations of Lyme disease ALS, by contrast, is relentless. Most patients with ALS experience steady, measurable decline month over month. A clinical picture that has been stable or only slowly worsening for years is more consistent with Lyme.
- Tick exposure and rash history: Living in or traveling to a region where Lyme is common, combined with a history of tick bites or a characteristic expanding rash, adds weight to the Lyme hypothesis. Many patients, however, never notice the tick or the rash, so the absence of these does not rule it out.
- Cerebrospinal fluid findings: When a lumbar puncture is performed, Lyme neuroborreliosis often produces elevated white blood cells and protein levels in the spinal fluid, along with antibodies against the Lyme bacterium. ALS typically does not cause an inflammatory spinal fluid profile. This is one of the most helpful distinguishing tests, though it comes with its own complications (discussed below).
Formal ALS diagnosis now follows criteria requiring evidence of both upper and lower motor neuron dysfunction, progressive spread to additional body regions, and the absence of other explanations for the findings.4PubMed. Diagnosing ALS: the Gold Coast criteria and the role of EMG That last requirement, ruling out alternative explanations, is precisely where Lyme testing enters the diagnostic workup. Neurologists working through a motor neuron disease case are supposed to exclude treatable mimics before settling on ALS, and neuroborreliosis is one of those mimics.
How Reliable Are Lyme Tests When ALS Is on the Table
Here is where things get messy. Standard Lyme testing relies on detecting antibodies in the blood, typically through a two-step process: an initial screening test followed by a confirmatory test. The sensitivity of this approach varies dramatically depending on how long the infection has been present. During early Lyme disease, before the body has mounted a full immune response, blood tests catch only about 30 to 50 percent of true infections.5PubMed Central. Current Guidelines, Common Clinical Pitfalls, and Future Directions for Laboratory Diagnosis of Lyme Disease, United States By the time neurological complications develop (which represents later-stage disease), sensitivity climbs considerably: a North American meta-analysis found sensitivity around 90 percent for stage 2 disease and above 99 percent for stage 3.6PLOS ONE. The Accuracy of Diagnostic Tests for Lyme Disease in Humans, A Systematic Review and Meta-Analysis of North American Research
European data tell a somewhat different story. A systematic review of European studies found that serological sensitivity for neuroborreliosis specifically was around 77 percent, lower than the North American figures for comparable disease stages.7PubMed Central. The diagnostic accuracy of serological tests for Lyme borreliosis in Europe: a systematic review and meta-analysis This discrepancy likely reflects differences in the Borrelia species involved (North America has primarily one species; Europe has several) and differences in test design. The practical takeaway is that a negative blood test does not completely rule out Lyme when the clinical picture is suspicious, especially in European patients.
Specificity, the ability of the test to correctly identify people who do not have Lyme, is generally high, above 95 percent in most studies. But “above 95 percent” still means a few percent of people without Lyme will test positive, and some of those false positives cluster among people with other neurological diseases that trigger cross-reacting antibodies. This matters a great deal in the ALS mimicry scenario, because a false-positive Lyme test in a patient who actually has ALS could send clinicians down the wrong treatment path.
What the ALS Population Data Show
A study of 414 ALS patients at Massachusetts General Hospital directly addressed the question of how often Lyme serology comes back positive in people who have confirmed ALS. About 6 percent tested seropositive, but when investigators dug deeper, fewer than 1 percent had evidence of a genuine past Lyme infection. Two of those patients received a month-long course of intravenous antibiotics without any clinical improvement.8PubMed. Lyme disease serology in amyotrophic lateral sclerosis The study’s conclusion was blunt: Lyme disease was rare in their ALS cohort and was not likely to be causing the disease.
This finding cuts both ways. On one hand, it should reassure patients and families that a positive Lyme test in someone with ALS does not mean the ALS diagnosis is wrong. Most of those positives are noise, not signal. On the other hand, it means that a small number of patients within a large ALS cohort may genuinely have had Lyme-related neurological damage, and even the investigators acknowledged that Lyme testing during an ALS workup remains appropriate in endemic areas, even if the hit rate is low.
Neurofilament Levels Can Help Distinguish the Two
One of the more promising developments in separating ALS from its mimics involves measuring neurofilament proteins in the blood or spinal fluid. Neurofilaments are structural proteins inside nerve cells, and when those cells are damaged or dying, neurofilament levels rise in the surrounding fluid. The key insight is that ALS destroys motor neurons at a much faster and more widespread rate than most of its mimics, so neurofilament levels tend to be dramatically higher in ALS than in conditions like neuropathies, nerve root inflammation, or muscle diseases.
A study comparing neurofilament levels across ALS patients and various ALS mimic conditions found that a specific neurofilament marker in spinal fluid could distinguish ALS from mimics with roughly 83 percent sensitivity and 83 percent specificity. Blood-based neurofilament testing performed almost as well, with about 76 percent sensitivity and 83 percent specificity.9PubMed Central. Neurofilaments can differentiate ALS subgroups and ALS from common diagnostic mimics These numbers are not perfect, but when combined with clinical assessment, imaging, and electrical nerve testing, they add a useful layer of evidence. A patient with an ALS-like presentation but relatively low neurofilament levels deserves a closer look for treatable alternatives, including neuroborreliosis.
Blood-based neurofilament testing is increasingly available and does not require a spinal tap, which makes it practical to add to the workup for patients where there is genuine diagnostic uncertainty. It is not yet standard at every center, but the trend in ALS diagnostics is moving toward incorporating it.
Why False Positives in Spinal Fluid Complicate Things Further
When Lyme neuroborreliosis is suspected, clinicians often test the spinal fluid for Lyme-specific antibodies. This is generally considered more reliable than blood testing for confirming active nervous system involvement. However, false-positive spinal fluid results do occur, and they create a genuinely difficult clinical dilemma. A case report highlighting this issue emphasized that comprehensive investigation is vital in motor neuron disease to avoid missing a treatable diagnosis, but cautioned that false-positive spinal fluid results must be interpreted carefully in the context of all other clinical findings.10PubMed Central. ALS or ALS mimic by neuroborreliosis-A case report
In practice, this means that a positive Lyme test in spinal fluid does not automatically override an ALS diagnosis. Clinicians weigh the test result against the full picture: Does the patient have sensory symptoms? Is there inflammation in the spinal fluid beyond just Lyme antibodies? Does the electrical nerve testing pattern look more like root inflammation than motor neuron death? Has there been tick exposure? Is the progression pattern typical for ALS or more consistent with Lyme? No single test result answers the question alone.
What Happens When the Real Culprit Is Lyme
For the small number of patients whose ALS-like symptoms are genuinely caused by Lyme, antibiotic treatment can be transformative. This is the entire reason the mimicry question matters: ALS has no disease-modifying cure, while neuroborreliosis responds to antibiotics, usually intravenous ceftriaxone. The difference in prognosis between the two diagnoses is about as stark as it gets in neurology.
Most uncomplicated Lyme neuroborreliosis responds to standard courses of antibiotics lasting two to four weeks. Some cases involving severe motor deficits or co-infections with other tick-borne pathogens require longer and more complex treatment. A case series of ten patients with severe motor deficits in the context of Borrelia infection (sometimes combined with other tick-borne organisms like Babesia and Anaplasma) found that seven out of ten achieved complete remission after treatment averaging about 20 months and involving multiple cycles of ceftriaxone.11PubMed Central. Complete Remission in Paralytic Late Tick-Borne Neurological Disease Comprising Mixed Involvement of Borrelia, Babesia, Anaplasma, and Bartonella That 70 percent complete remission rate in patients with intractable or severe motor problems is remarkable, though this was a small series and the treatment durations were far longer than standard guidelines recommend.
The contrast with the Massachusetts General Hospital data is instructive. In that study, two confirmed-Lyme-positive ALS patients who received ceftriaxone did not improve, suggesting they had true ALS with an incidental positive Lyme test rather than Lyme mimicking ALS.8PubMed. Lyme disease serology in amyotrophic lateral sclerosis When antibiotics fail to produce any improvement after an adequate trial, the diagnosis almost certainly is ALS and not Lyme. Response to treatment functions as a kind of diagnostic test in itself.
When Co-Infections Muddy the Picture
Ticks that carry Borrelia burgdorferi, the Lyme bacterium, frequently carry other pathogens at the same time. Babesia (a malaria-like parasite), Anaplasma, and Bartonella are among the most common co-travelers. Co-infections can amplify or alter the neurological presentation, potentially making it harder to recognize the pattern as tick-borne rather than degenerative. The case series mentioned above found that most of its patients with severe motor deficits had infections with two or more tick-borne organisms, not just Borrelia alone.11PubMed Central. Complete Remission in Paralytic Late Tick-Borne Neurological Disease Comprising Mixed Involvement of Borrelia, Babesia, Anaplasma, and Bartonella
Co-infections may also explain why some patients require far longer treatment courses than the standard two to four weeks. Standard Lyme testing does not screen for these additional organisms, so if a patient has a confirmed Lyme infection but is not improving with appropriate antibiotics, testing for co-infections is a reasonable next step. This is a contested area in infectious disease medicine, with mainstream guidelines generally cautious about prolonged antibiotic courses and some clinicians advocating more aggressive and extended treatment. The evidence base remains thin, relying mostly on case series rather than large trials.
Practical Steps for Patients and Families
If you or someone you know has received a possible ALS diagnosis and lives in or has traveled to a Lyme-endemic area, asking the neurologist whether Lyme testing has been done is reasonable and appropriate. Most ALS specialists in endemic regions already include it as part of their standard workup. The key tests are blood-based Lyme serology and, if that is positive or the clinical suspicion is high, a lumbar puncture to check for spinal fluid antibodies, inflammatory cells, and protein levels.
A few practical considerations are worth keeping in mind. A positive blood test alone, without supporting clinical features like sensory symptoms, pain, or inflammatory spinal fluid, is more likely to be a false positive than evidence of active neuroborreliosis. The 6 percent seropositivity rate among confirmed ALS patients at a major medical center illustrates this well. Conversely, a negative blood test in very early disease or in patients from Europe does not completely exclude Lyme, so if the clinical presentation has atypical features for ALS, further investigation may still be warranted.
For patients already diagnosed with ALS who are considering Lyme testing on their own, it is worth understanding that the internet has amplified an understandable hope: that what looks like an untreatable disease might actually be a curable infection. The documented cases where this turned out to be true are real but rare. Pursuing Lyme testing is low-risk and worthwhile. Pursuing prolonged courses of antibiotics based on equivocal test results without neurological improvement, however, carries its own costs and complications.
The Role of Electrical Nerve Testing
Electromyography (EMG) and nerve conduction studies play a central role in the ALS workup and can sometimes help distinguish Lyme mimicry from true motor neuron disease, though the overlap on these tests is one of the reasons the mimicry is so convincing. In the case of the 64-year-old man with Lyme-induced weakness, initial electrical testing showed widespread active and chronic denervation, exactly the pattern expected in ALS.1PubMed. Lyme disease-induced polyradiculopathy mimicking amyotrophic lateral sclerosis This finding underscores that EMG alone cannot reliably separate the two conditions.
Where electrical testing sometimes helps is in the pattern of abnormalities. Lyme radiculopathy tends to affect nerve roots in a distribution that corresponds to specific spinal levels, sometimes with abnormal sensory nerve responses. ALS produces denervation that crosses spinal levels and root territories in a pattern more consistent with scattered motor neuron death than with root-level damage. Nerve conduction studies may also show slowed conduction velocities or conduction block in Lyme cases, suggesting a demyelinating process (damage to the nerve’s insulating sheath) rather than pure axonal loss. These distinctions are subtle and require an experienced electrophysiologist to interpret, but they can provide additional evidence when the diagnosis is uncertain.
How the Lyme Bacterium Damages Nerves Differently Than ALS
The underlying mechanisms are fundamentally different, even when the surface presentation looks the same. ALS involves the progressive death of motor neurons in the brain and spinal cord through mechanisms that are still not fully understood but involve protein misfolding, oxidative stress, and genetic factors. The damage is intrinsic to the motor neurons themselves.
Lyme neuroborreliosis, by contrast, damages the nervous system from the outside in. The bacterium triggers inflammation of the meninges (the membranes around the brain and spinal cord), blood vessel walls, and nerve roots. In the spinal cord, researchers have documented focal areas of tissue destruction in the cervical region, along with inflammation and nerve cell death in the clusters of sensory nerve cell bodies near the spine.2PubMed Central. Inflammation in the pathogenesis of lyme neuroborreliosis This inflammatory, infectious process is what makes the condition treatable: eliminate the bacterium and the inflammatory cascade can resolve, allowing surviving nerve tissue to recover function. In ALS, there is no external invader to target, and the neuron death, once it occurs, is irreversible.
This mechanistic difference also explains why the clinical trajectories tend to diverge over time even when the initial snapshots look similar. Chronic Lyme neurological disease often stabilizes or fluctuates, sometimes waxing and waning in response to the immune system’s activity against the bacterium. ALS does not fluctuate. It progresses. A patient whose weakness has been present for over a year with minimal change is behaving much more like a Lyme case than an ALS case, even if the initial workup was concerning for motor neuron disease.